Header Logo

Connection

Parameswaran Venugopal to Humans

This is a "connection" page, showing publications Parameswaran Venugopal has written about Humans.
Connection Strength

0.451
  1. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol. 2017 Apr; 177(1):72-79.
    View in: PubMed
    Score: 0.031
  2. Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
    View in: PubMed
    Score: 0.028
  3. A patient with necrobiotic xanthogranuloma presenting with an anterior mediastinal mass, plasma cell dyscrasia, and a lymphoproliferative disorder. Clin Adv Hematol Oncol. 2011 Sep; 9(9):696-700.
    View in: PubMed
    Score: 0.022
  4. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104.
    View in: PubMed
    Score: 0.021
  5. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011 Apr 01; 117(7):1490-7.
    View in: PubMed
    Score: 0.020
  6. Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jun; 10(8):1353-7.
    View in: PubMed
    Score: 0.018
  7. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol. 2008 Aug; 6(8):587-90.
    View in: PubMed
    Score: 0.017
  8. Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation. Clin Adv Hematol Oncol. 2007 Apr; 5(4):320-3; discussion 323-4.
    View in: PubMed
    Score: 0.016
  9. Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol. 2006 Mar; 4(3):215-7; discussion 217-8.
    View in: PubMed
    Score: 0.015
  10. Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy. Clin Adv Hematol Oncol. 2005 Feb; 3(2):136-9; discussion 139-40.
    View in: PubMed
    Score: 0.014
  11. Lymphomatoid granulomatosis treated with rituximab and chemotherapy. Clin Adv Hematol Oncol. 2003 Nov; 1(11):658-60; discussion 660.
    View in: PubMed
    Score: 0.013
  12. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 06; 98(6):900-912.
    View in: PubMed
    Score: 0.012
  13. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 05; 64(5):1026-1034.
    View in: PubMed
    Score: 0.012
  14. Venetoclax ramp-up with concurrent voriconazole in a patient with chronic lymphocytic leukemia. J Oncol Pharm Pract. 2022 Dec; 28(8):1898-1901.
    View in: PubMed
    Score: 0.011
  15. Impact of blood type on thrombosis and disease severity in adult COVID-19 patients. Thromb Res. 2021 10; 206:145-147.
    View in: PubMed
    Score: 0.011
  16. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 12 01; 127(23):4421-4431.
    View in: PubMed
    Score: 0.011
  17. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021 07 27; 5(14):2852-2862.
    View in: PubMed
    Score: 0.011
  18. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica. 2021 07 01; 106(7):1932-1942.
    View in: PubMed
    Score: 0.011
  19. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021 01 21; 137(3):374-386.
    View in: PubMed
    Score: 0.010
  20. Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2020 08; 61(8):2008-2011.
    View in: PubMed
    Score: 0.010
  21. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 10; 38(5):1448-1453.
    View in: PubMed
    Score: 0.010
  22. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407.
    View in: PubMed
    Score: 0.009
  23. Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019 07; 186(1):45-53.
    View in: PubMed
    Score: 0.009
  24. When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):e251-e258.
    View in: PubMed
    Score: 0.009
  25. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
    View in: PubMed
    Score: 0.009
  26. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 01; 35(31):3538-3546.
    View in: PubMed
    Score: 0.008
  27. Impact of cachexia on outcomes in aggressive lymphomas. Ann Hematol. 2017 Jun; 96(6):951-956.
    View in: PubMed
    Score: 0.008
  28. Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. Chemotherapy. 2017; 62(2):140-146.
    View in: PubMed
    Score: 0.008
  29. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
    View in: PubMed
    Score: 0.007
  30. All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. Blood Rev. 2015 Mar; 29(2):71-80.
    View in: PubMed
    Score: 0.007
  31. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. J Leukoc Biol. 2013 Jan; 93(1):161-70.
    View in: PubMed
    Score: 0.006
  32. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104.
    View in: PubMed
    Score: 0.006
  33. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012 Feb; 10(2):134-6.
    View in: PubMed
    Score: 0.006
  34. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
    View in: PubMed
    Score: 0.005
  35. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma. 2008 Sep; 49(9):1681-92.
    View in: PubMed
    Score: 0.004
  36. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 May; 7(6):406-12.
    View in: PubMed
    Score: 0.004
  37. Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation. Clin Adv Hematol Oncol. 2006 Aug; 4(8):600-4; discussion 604-6.
    View in: PubMed
    Score: 0.004
  38. Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab. Clin Adv Hematol Oncol. 2006 Jun; 4(6):439-41.
    View in: PubMed
    Score: 0.004
  39. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma. Clin Lymphoma. 2005 Jun; 6(1):26-30.
    View in: PubMed
    Score: 0.003
  40. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004 Aug; 28(8):791-803.
    View in: PubMed
    Score: 0.003
  41. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. Clin Adv Hematol Oncol. 2004 Apr; 2(4):229-33.
    View in: PubMed
    Score: 0.003
  42. Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res. 2003 Aug; 12(4):443-50.
    View in: PubMed
    Score: 0.003
  43. A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. Leuk Res. 2003 Jun; 27(6):529-37.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.